At a glance
ClinicalIndex Comparison RecordN/ACompleted· 53,969 enrolled
Drug / intervention
warfarin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)
In Brief
An observational study evaluating warfarin, dabigatran, and 3 other interventions for Atrial Fibrillation. Completed, enrolled 53,969 participants across 1 site.
Detailed Summary
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartOct 2017
Primary CompletionOct 2017
Study CompletionNov 2017
TodayJul 2026
First PostedAug 18, 2017
Enrollment StartOct 15, 2017
Primary CompletionOct 30, 2017
Study CompletionNov 10, 2017
TodayJul 2, 2026
Enrollment to primary: 15 daysPosted 8.9 years ago
Interventions
warfarindrug
warfarin
dabigatrandrug
Non-vitamin K dependent oral anti-coagulants (NOACs)
Apixabandrug
Non-vitamin K dependent oral anti-coagulants (NOACs)
Edoxabandrug
Non-vitamin K dependent oral anti-coagulants (NOACs)
Rivaroxabandrug
Non-vitamin K dependent oral anti-coagulants (NOACs)